Research programme: calprotectin inhibitors - Kaneka/Teikyo University/Tokyo University
Latest Information Update: 08 Apr 2008
At a glance
- Originator Kaneka; Teikyo University; Tokyo University of Science
- Developer Kaneka
- Class Alkaloids
- Mechanism of Action Leukocyte L1 antigen complex antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 28 Sep 1999 Preclinical development for Inflammation in Japan (Unknown route)